Last edition
News about "Spyre Therapeutics "
Spyre Therapeutics Initiates Dosing of First Participant in Phase 1 Trial of SPY003
The SPY003 Phase 1 Trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study in healthy volunteers.
Spyre Therapeutics | 31/03/2025 | By Aishwarya | 187
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members